The tumor microenvironment and inflammatory response are hallmarks of cancer progression. The NLR emerged as an indicator of the inflammatory state in patients with cancer, and has been negatively correlated with the prognosis of several solid tumors including mCRPC. The NLR is an available and easy to use tool and the authors assessed its role in the prognosis and response duration of patients treated with AA.
Retrospectively evaluated clinical data of patients with mCRPC from a single high volume center, with disease evaluable according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria, that underwent at least 12 weeks of AA. NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count in the peripheral blood at baseline and at 12 weeks of treatment. NLR was stratified in two groups, > 5 and
112 patients were treated with AA between 01/01/2013 and 31/12/2015, 90 for at least 12 weeks. The average NLR was 4,35 ± 3,07 (1,15-22,10). 33 had a NLR > 5 (36,7%), with both groups characteristics balanced. Median OS was 16,6 months in the NLR > 5 group and 27,1 months in the NLR 5 at baseline converted to 5 group and 9,7 months in the NLR
The NLR was prognostic in this analysis, with a NLR > 5 at baseline associated to a worse OS. There was no relation between NLR and response duration, with similar PFS in both groups. There was a trend for better OS in patients with a NLR > 5 at baseline that converted to
Clinical trial identification
Legal entity responsible for the study
Centro Hospitalar Lisboa Norte, Hospital de Santa Maria
Serviço de Oncologia Médica, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria
All authors have declared no conflicts of interest.